CYYNF (Cynata Therapeutics) Ending Cash Position: $1.72 Mil (As of Dec. 2025)


What is Cynata Therapeutics Ending Cash Position?

Cynata Therapeutics CYYNF Ending Cash Position is $1.72 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Cynata Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was $1.72 Mil.

Cynata Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 ($6.66 Mil) to Jun. 2025 ($3.29 Mil) and declined from Jun. 2025 ($3.29 Mil) to Dec. 2025 ($1.72 Mil).

Cynata Therapeutics's annual Ending Cash Position declined from Jun. 2023 ($10.85 Mil) to Jun. 2024 ($4.12 Mil) and declined from Jun. 2024 ($4.12 Mil) to Jun. 2025 ($3.29 Mil).

Cynata Therapeutics Ending Cash Position Related Terms

Cynata Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Cynata Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cynata Therapeutics Ending Cash Position Chart

Cynata Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.43 16.72 10.85 4.12 3.29

Cynata Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.48 4.12 6.66 3.29 1.72

Cynata Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cynata Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.04+-0.752
=3.29

Cynata Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.357+-1.637
=1.72

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.72 Mil mean?
Cynata Therapeutics (CYYNF) has a Ending Cash Position of $1.72 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cynata Therapeutics and its competitors.
Is Cynata Therapeutics' Ending Cash Position too high?
Cynata Therapeutics' current Ending Cash Position is $1.72 Mil.
How does Cynata Therapeutics' Ending Cash Position compare to VRTX and REGN?
Cynata Therapeutics' Ending Cash Position of $1.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cynata Therapeutics and its competitors. Cynata Therapeutics's current Ending Cash Position is $1.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current Ending Cash Position of $1.72 Mil. The current Ending Cash Position is $1.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current Ending Cash Position is $1.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cynata Therapeutics Business Description

Other Exchanges 51S:GermanyCYP:Australia
Address 100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.